Cargando…

Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium

BACKGROUND: The role of the tumor necrosis factor receptor associated protein 1 (TRAP1) – supposed to be involved in protection of cells from apoptosis and oxidative stress – has just started to be investigated in ovarian cancer. TRAP1 has been shown to be estrogen up-regulated in estrogen receptor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aust, Stefanie, Bachmayr-Heyda, Anna, Pateisky, Petra, Tong, Dan, Darb-Esfahani, Silvia, Denkert, Carsten, Chekerov, Radoslav, Sehouli, Jalid, Mahner, Sven, Van Gorp, Toon, Vergote, Ignace, Speiser, Paul, Horvat, Reinhard, Zeillinger, Robert, Pils, Dietmar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533746/ https://www.ncbi.nlm.nih.gov/pubmed/22978347 http://dx.doi.org/10.1186/1476-4598-11-69

Ejemplares similares

Ambivalent role of pFAK-Y397 in serous ovarian cancer-a study of the OVCAD consortium
por: Aust, Stefanie, et al.
Publicado: (2014)

Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients - a study of the OVCAD consortium
por: Bachmayr-Heyda, Anna, et al.
Publicado: (2013)

A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer - a study of the OVCAD consortium
por: Pils, Dietmar, et al.
Publicado: (2013)

Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium
por: Trillsch, Fabian, et al.
Publicado: (2013)

Association of a Combined Cancer Exhaustion Score with Circulating Tumor Cells and Outcome in Ovarian Cancer—A Study of the OVCAD Consortium
por: Obermayr, Eva, et al.
Publicado: (2021)

The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer—A Study of the OVCAD Consortium
por: Obermayr, Eva, et al.
Publicado: (2021)

HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer – a study of the OVCAD Consortium
por: Braicu, Elena Ioana, et al.
Publicado: (2014)

Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium
por: Obermayr, Eva, et al.
Publicado: (2017)

Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) – a study of the TOC Consortium
por: Braicu, Elena Ioana, et al.
Publicado: (2014)

Peritoneal tumor spread in serous ovarian cancer-epithelial mesenchymal status and outcome
por: Auer, Katharina, et al.
Publicado: (2015)

Biomarker-Based Models for Preoperative Assessment of Adnexal Mass: A Multicenter Validation Study
por: Watrowski, Rafał, et al.
Publicado: (2022)

Two different, mutually exclusively distributed, TP53 mutations in ovarian and peritoneal tumor tissues of a serous ovarian cancer patient: indicative for tumor origin?
por: Sukhbaatar, Nyamdelger, et al.
Publicado: (2017)

A Global Gene Body Methylation Measure Correlates Independently with Overall Survival in Solid Cancer Types
por: Pils, Dietmar, et al.
Publicado: (2020)

Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer
por: Mungenast, Felicitas, et al.
Publicado: (2017)

Clinical Significance of Organic Anion Transporting Polypeptide Gene Expression in High-Grade Serous Ovarian Cancer
por: Svoboda, Martin, et al.
Publicado: (2018)

Correlation of circular RNA abundance with proliferation – exemplified with colorectal and ovarian cancer, idiopathic lung fibrosis, and normal human tissues
por: Bachmayr-Heyda, Anna, et al.
Publicado: (2015)

Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer
por: Auer, Katharina, et al.
Publicado: (2016)

EV-Associated MMP9 in High-Grade Serous Ovarian Cancer Is Preferentially Localized to Annexin V-Binding EVs
por: Reiner, Agnes T., et al.
Publicado: (2017)

Definition and Independent Validation of a Proteomic-Classifier in Ovarian Cancer
por: Kasimir-Bauer, Sabine, et al.
Publicado: (2020)

Small RNAs and the competing endogenous RNA network in high grade serous ovarian cancer tumor spread
por: Bachmayr-Heyda, Anna, et al.
Publicado: (2016)

AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer
por: Svoboda, Martin, et al.
Publicado: (2016)

Discovery and Validation of Novel Biomarkers for Detection of Epithelial Ovarian Cancer
por: Kulbe, Hagen, et al.
Publicado: (2019)

Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer
por: Aust, Stefanie, et al.
Publicado: (2017)

Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer
por: Woopen, Hannah, et al.
Publicado: (2014)

Lavage of the Uterine Cavity for Molecular Detection of Müllerian Duct Carcinomas: A Proof-of-Concept Study
por: Maritschnegg, Elisabeth, et al.
Publicado: (2015)

Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).
por: Ruscito, Ilary, et al.
Publicado: (2018)

Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group
por: Trillsch, Fabian, et al.
Publicado: (2021)

Interrelations of Sphingolipid and Lysophosphatidate Signaling with Immune System in Ovarian Cancer
por: Meshcheryakova, Anastasia, et al.
Publicado: (2019)

Stable expansion of high‐grade serous ovarian cancer organoids requires a low‐Wnt environment
por: Hoffmann, Karen, et al.
Publicado: (2020)

An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas
por: Noske, Aurelia, et al.
Publicado: (2011)

Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer()
por: Stanske, Mandy, et al.
Publicado: (2018)

Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium
por: Ray-Coquard, Isabelle, et al.
Publicado: (2019)

The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer
por: Aust, Stefanie, et al.
Publicado: (2013)

Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma
por: Darb-Esfahani, Silvia, et al.
Publicado: (2015)

Checkpoint-inhibition in ovarian cancer: rising star or just a dream?
por: Pietzner, Klaus, et al.
Publicado: (2018)

Organoids of epithelial ovarian cancer as an emerging preclinical in vitro tool: a review
por: Dumont, Sander, et al.
Publicado: (2019)

Proteomic biomarkers predicting lymph node involvement in serum of cervical cancer patients. Limitations of SELDI-TOF MS
por: Van Gorp, Toon, et al.
Publicado: (2012)

High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism
por: Braicu, Elena Ioana, et al.
Publicado: (2017)

Can a morphological description of the peritoneal carcinomatosis in advanced ovarian cancer add prognostic information? Analysis of 1686 patients of the tumor bank ovarian cancer
por: Nasser, Sara, et al.
Publicado: (2022)

Correction: Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers
por: Gschwantler-Kaulich, Daphne, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_a8p3p2jhbj5i16bsrbde3185o2